Discover which prostate cancer patient groups (metastatic, progressing to metastatic) show the greatest benefit from novel therapies like NXP800 and next-gen hormone inhibitors, based on 2025 clinical trial data.
Table of Contents
Question
Based on the study’s findings, which patients may benefit the most from the development of new treatments for prostate cancer? (Select all that apply)
A. Patients receiving only one line of treatment in the in situ group
B. Patients progressing from in situ to metastatic disease
C. Patients receiving two lines of treatment in the in situ group
D. Patients with in situ disease
E. Patients with metastatic disease
Answer
B. Patients progressing from in situ to metastatic disease
E. Patients with metastatic disease
Explanation
Recent studies highlight that patients with metastatic prostate cancer (E) and those progressing from in situ to metastatic disease (B) derive the most benefit from emerging therapies. Here’s why:
Patients with metastatic disease (E)
New androgen receptor pathway inhibitors (ARPIs) like enzalutamide and abiraterone significantly improve survival in advanced cases. After five years, 60% of men on these drugs survived vs. 44% with standard hormone therapy alone.
NXP800, a drug targeting heat shock proteins, slows tumor growth even in hormone-resistant metastatic cancers.
Immunotherapy using nanoparticles delays hormone therapy resistance, extending survival in metastatic settings.
Patients progressing from in situ to metastatic disease (B)
Resistance to hormone therapy is a critical challenge during progression. NXP800 and immunotherapy directly address this by disrupting pathways like HSF1 and activating immune responses.
Studies show higher heat shock protein levels in progressing tumors correlate with worse outcomes, making these patients ideal candidates for targeted therapies.
Why other options are less supported
In situ disease (D) and single/two-line in situ treatments (A/C) lack evidence in the studies, which focus on advanced/metastatic stages. New therapies prioritize overcoming resistance in aggressive, late-stage cases.
Data Science with Real World Data in Pharma certification exam assessment practice question and answer (Q&A) dump including multiple choice questions (MCQ) and objective type questions, with detail explanation and reference available free, helpful to pass the Data Science with Real World Data in Pharma exam and earn Data Science with Real World Data in Pharma certification.